DelRocco, N. J. http://orcid.org/0000-0002-8139-9839
Loh, M. L. http://orcid.org/0000-0003-4099-4700
Borowitz, M. J.
Gupta, S.
Rabin, K. R. http://orcid.org/0000-0002-4081-8195
Zweidler-McKay, P.
Maloney, K. W.
Mattano, L. A. http://orcid.org/0000-0002-8409-0589
Larsen, E.
Angiolillo, A.
Schore, R. J. http://orcid.org/0000-0002-1582-2168
Burke, M. J. http://orcid.org/0000-0001-6626-2773
Salzer, W. L.
Wood, B. L.
Carroll, A. J. http://orcid.org/0000-0001-9844-730X
Heerema, N. A.
Reshmi, S. C.
Gastier-Foster, J. M.
Harvey, R.
Chen, I. M.
Roberts, K. G. http://orcid.org/0000-0001-7626-4043
Mullighan, C. G. http://orcid.org/0000-0002-1871-1850
Willman, C.
Winick, N. http://orcid.org/0000-0002-6636-3870
Carroll, W. L. http://orcid.org/0000-0003-1550-4167
Rau, R. E.
Teachey, D. T. http://orcid.org/0000-0001-7373-8987
Hunger, S. P.
Raetz, E. A. http://orcid.org/0000-0002-8547-1658
Devidas, M. http://orcid.org/0000-0002-1099-3478
Kairalla, J. A.
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (U10 CA180886, U24 CA114766, U24 CA196173, U10 CA98543, U10 CA98413, U10 CA180899)
St. Baldrick's Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35 CA197695)
Article History
Received: 5 September 2023
Revised: 15 January 2024
Accepted: 23 January 2024
First Online: 15 February 2024
Competing interests
: MJB has been on an advisory board and received honoraria from Amgen and received honoraria from Blueprint Medicines; JAK owns common stock in Johnson & Johnson. PZM employment at ImmunoGen. BW has served as a consultant for Amgen and has received research funding from Celgene/Juno, Kite, Novartis, Wugen, Macrogenics, Biosight, and Beam; EAR has received institutional research funding from Pfizer and serves on a DSMB for Celgene/BMS; SPH owns common stock in Amgen and has received honoraria from Amgen, Jazz, and Servier. WLC serves as a consultant for Merck. LAM has received consulting fees from Novartis and Pfizer, and owns stock in Pfizer. CGM serves on an advisory board for Illumina; has received research funding from Pfizer, AbbVie; and receives royalties from Cyrus.